Pfizer stock steadies as new XFG COVID-19 shot wins FDA approval and oncology growth builds

Pfizer stock trades in the high-$27 range as of August 31, 2026, while a newly approved XFG-adapted Comirnaty COVID-19 vaccine and gradually expanding oncology revenues shape the company’s turnaround story.

Pfizer Inc. (US7170811035) stock is holding around the high-$27 range as of August 31, 2026, with investors weighing a fresh US approval for its updated XFG-adapted Comirnaty COVID-19 vaccine against a gradual recovery in oncology growth and dividend income that yields more than 6 percent.  A recent market session saw Pfizer shares settle at $27.96, underscoring a relatively steady trading band while new product catalysts emerge and longer-term earnings expectations edge higher.

FDA backs XFG-adapted Comirnaty for fall rollout

A key near-term catalyst for Pfizer is US regulatory clearance for Comirnaty XFG, the 2026–2027 XFG-adapted mRNA COVID-19 vaccine formulation developed with BioNTech for higher-risk patient groups.  According to a report on the approval, the US Food and Drug Administration has granted a supplemental Biologics License Application for Comirnaty XFG covering adults aged 65 and older and individuals aged 5 through 64 with at least one underlying condition that raises the risk of severe COVID-19 outcomes, with shipping beginning immediately after approval as of August 31, 2026. The Comirnaty XFG approval summary notes that the XFG strain was selected based on FDA guidance for US COVID-19 vaccines starting in fall 2026.

The fall 2026 rollout positions Pfizer to capture seasonal booster demand in a more focused risk segment after earlier pandemic waves and changing variant patterns.  Because the FDA has framed XFG as the preferred composition for the upcoming season, the company can align its manufacturing and distribution plans more tightly with US guidance, potentially supporting vaccine revenue stability even as broader COVID-19 sales have normalized in recent years.  For investors, this targeted authorization adds a concrete regulatory milestone that could translate into incremental vaccine revenue during the 2026–2027 season, especially if high-risk groups maintain strong booster uptake.

Oncology revenues edge higher in Q2 2026

Beyond vaccines, Pfizer is leaning on oncology as a strategic growth pillar, with recent figures indicating modest but positive progress.  In the second quarter of 2026, oncology revenues rose 3 percent to $4.17 billion, including 2 percent operational growth, supported by medicines such as Padcev, Lorbrena and the Braftovi/Mektovi combination. An oncology-focused overview highlights that Pfizer aims to expand labels for multiple approved cancer therapies while building a pipeline expected to deliver eight or more blockbuster oncology medicines by 2030.

The same overview underscores that Pfizer’s pipeline now includes several late-stage oncology candidates, including atirmociclib and sigvotatug vedotin, as well as a regulatory application for sasanlimab under review in the European Union.  A central element of the strategy is PF-08634404, a dual PD-1/VEGF inhibitor in-licensed in 2025, for which Pfizer has initiated nine studies, including two pivotal phase III trials in first-line metastatic colorectal cancer and first-line non-small cell lung cancer, plus phase II studies in small-cell lung cancer and gastroesophageal cancers.  This breadth of trials illustrates how Pfizer is attempting to create a backbone therapy across several tumor types, a move that could materially lift oncology revenues if the candidate succeeds and supports the company’s goal of having eight or more oncology blockbusters by the end of the decade.

Dividend, valuation and consensus expectations

Income investors continue to focus on Pfizer’s dividend stream, which remains sizable relative to the share price.  One recent analysis notes that Pfizer’s forward annualized dividend stands at $1.72 per share, paid quarterly at $0.43, representing a yield of about 6.2 percent at prevailing share levels; another dividend-focused overview cites a current annual dividend of $1.68 per share translating into a yield of roughly 6.18 percent based on a late-August price of $27.96. A dividend-oriented turnaround discussion frames this payout as a meaningful component of total return for shareholders as the company rebuilds earnings momentum.

From a valuation standpoint, the same oncology-focused article reports that Pfizer shares trade at 9.48 times forward earnings, compared with a sector multiple of 18.71 and a five-year company mean of 9.25.  That implies a discount of 49 percent versus the broader industry multiple, while the stock is slightly above its own historical average valuation, a combination that can appeal to investors seeking both value and a credible earnings recovery narrative.  Consensus expectations have also shifted modestly upward: the 2026 earnings-per-share estimate has moved from $2.96 to $2.98 over the past 30 days, and the 2027 estimate has increased from $2.85 to $2.94 during the same period, signaling incremental confidence in Pfizer’s ability to convert its pipeline and cost measures into higher profit.

One institutional-holding overview shows that the stock currently carries a consensus rating labeled Hold, with an average published target price of $28.28.  Compared with the recent trading level of $27.96, that average target implies a modest upside of $0.32 per share, or about 1.1 percent, reflecting a cautious but not negative stance among covering analysts.  Taken together, the dividend yield in the low-6-percent range, the forward price-earnings ratio of 9.48 versus 18.71 for the sector, and a slight upward drift in consensus earnings estimates paint a picture of a large-cap biopharmaceutical company viewed as value-leaning, with investors waiting for clearer evidence that new products and oncology growth can drive sustained earnings expansion.

Stock performance, volatility and year-to-date move

Pfizer’s share performance in 2026 has begun to stabilize after earlier pandemic-related swings and pipeline setbacks.  An oncology-focused valuation summary states that Pfizer stock has risen 12.3 percent year to date compared with a 13.9 percent increase for its industry peer group, indicating that the shares have slightly lagged the broader sector but still delivered double-digit appreciation so far in 2026.  Another trading commentary reports that PFE stock has fallen by 5 percent over a separate year-to-date window, a discrepancy that likely reflects differing start dates or index baselines across data providers, but both figures suggest that investors have experienced a choppy trajectory with periods of recovery offset by intermittent pressure tied to trial outcomes and macro sentiment.

Looking at shorter-term trading, a recent television-linked market recap notes that Pfizer shares fell 0.2 percent to settle at $27.96 during a session in late August 2026.  Against the average analyst target price of $28.28 cited in institutional-holding data, that closing level places the stock close to consensus expectations and supports the idea of a relatively tight trading range in the high-$27 to low-$28 band.  For investors focused on volatility, the narrow distance between the spot price and the average target underscores that any meaningful upside will likely depend on fresh clinical or regulatory catalysts, as well as clearer signals that oncology and vaccine revenues can translate into higher sustainable earnings growth.

Comirnaty XFG as a representative Pfizer product

Comirnaty XFG serves as a representative example of Pfizer’s ongoing vaccine innovation and its response to evolving public health guidance.  This XFG-adapted COVID-19 vaccine formulation is designed to provide active immunization against COVID-19 for adults 65 and older and for individuals aged 5 through 64 who have at least one underlying condition associated with a higher risk of severe disease.  The recently approved version for the 2026–2027 season reflects the FDA’s view that the XFG strain composition should be used for US COVID-19 vaccines heading into fall 2026, meaning that Pfizer has aligned its product design with updated regulatory expectations and variant surveillance.

For patients and physicians, Comirnaty XFG offers an option tailored to the current strain landscape and targeted to those who benefit most from booster protection, rather than a broad population rollout.  For Pfizer, the product extends the company’s COVID-19 franchise into another season while potentially smoothing revenue trends by focusing on higher-value risk segments, a strategy that could complement the company’s efforts to diversify its portfolio with oncology, immunology and other therapeutic pillars.

Pfizer stock and investor takeaway

Pfizer stock most recently settled at $27.96 in late August 2026 on the New York Stock Exchange, denominated in USD, a level that leaves the shares trading just below the average published analyst target of $28.28 and supporting a dividend yield in the low-6-percent range.

Fact box

Company: Pfizer Inc.

ISIN: US7170811035

Ticker: PFE

Exchange: NYSE

Market cap: Large-cap biopharmaceutical (value not specified in the latest excerpts)

Sector / Industry: Health care / Pharmaceuticals and biotechnology

Index membership: S&P 500